CORINDUS VASCULAR ROBOTICS, INC., 10-Q filed on 5/15/2015
Quarterly Report
Document and Entity Information
3 Months Ended
Mar. 31, 2015
May 14, 2015
Document And Entity Information [Abstract]
 
 
Document Type
10-Q 
 
Amendment Flag
false 
 
Document Period End Date
Mar. 31, 2015 
 
Document Fiscal Year Focus
2015 
 
Document Fiscal Period Focus
Q1 
 
Trading Symbol
CVRS 
 
Entity Registrant Name
Corindus Vascular Robotics, Inc. 
 
Entity Central Index Key
0001528557 
 
Current Fiscal Year End Date
--12-31 
 
Entity Filer Category
Smaller Reporting Company 
 
Entity Common Stock, Shares Outstanding
 
105,883,157 
Condensed Consolidated Balance Sheets (Unaudited) (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2015
Dec. 31, 2014
Current Assets:
 
 
Cash and cash equivalents
$ 22,015 
$ 28,526 
Accounts receivable
222 
473 
Due from related party
125 
 
Inventories, net
1,640 
1,519 
Prepaid expenses and other current assets
532 
574 
Total current assets
24,534 
31,092 
Property and equipment, net
1,313 
1,284 
Deposits and other assets
215 
222 
Deferred inventory costs
 
102 
Notes receivable due from stockholders
136 
136 
Total assets
26,198 
32,836 
Current Liabilities:
 
 
Accounts payable
2,445 
2,005 
Accrued expenses
1,202 
1,137 
Deferred revenue
167 
202 
Current portion of long-term debt
2,591 
1,517 
Total current liabilities
6,405 
4,861 
Long-term liabilities:
 
 
Deferred revenue, net of current portion
343 
531 
Other liabilities
62 
68 
Long-term debt, net of current portion
6,677 
7,594 
Total long-term liabilities
7,082 
8,193 
Total liabilities
13,487 
13,054 
Commitments and Contingencies
   
   
Stockholders' equity:
 
 
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued and outstanding
   
   
Common stock, $0.0001 par value; 250,000,000 shares authorized; 105,883,157 shares issued and outstanding
11 
11 
Additional paid-in capital
104,746 
104,648 
Accumulated deficit
(92,046)
(84,877)
Total stockholders' equity
12,711 
19,782 
Total liabilities and stockholders' equity
$ 26,198 
$ 32,836 
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Statement of Financial Position [Abstract]
 
 
Preferred stock, par value
$ 0.0001 
$ 0.0001 
Preferred stock, authorized shares
10,000,000 
10,000,000 
Preferred stock, issued shares
Preferred stock, outstanding shares
Common stock, par value
$ 0.0001 
$ 0.0001 
Common stock, authorized shares
250,000,000 
250,000,000 
Common stock, issued shares
105,883,157 
105,883,157 
Common stock, outstanding shares
105,883,157 
105,883,157 
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Income Statement [Abstract]
 
 
Revenue
$ 776 
$ 730 
Cost of revenue
801 
1,383 
Gross loss
(25)
(653)
Operating expenses:
 
 
Research and development
2,763 
2,046 
Selling, general and administrative
3,984 
2,810 
Restructuring charge
 
93 
Total operating expense
6,747 
4,949 
Operating loss
(6,772)
(5,602)
Other income (expense):
 
 
Warrant revaluation
 
1,765 
Interest and other income (expense)
(397)
Total other income (expense), net
(397)
1,768 
Net loss and comprehensive loss
$ (7,169)
$ (3,834)
Net loss per share-basic and diluted
$ (0.07)
$ (0.05)
Weighted-average common shares used in computing net loss per share-basic and diluted
105,883,157 
73,360,287 
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)
In Thousands, except Share data
Total
Common Stock $0.0001 Par Value [Member]
Additional Paid in Capital [Member]
Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2014
$ 19,782 
$ 11 
$ 104,648 
$ (84,877)
Beginning balance, shares at Dec. 31, 2014
 
105,883,157 
 
 
Stock-based compensation expense
98 
 
98 
 
Net loss
(7,169)
 
 
(7,169)
Ending balance at Mar. 31, 2015
$ 12,711 
$ 11 
$ 104,746 
$ (92,046)
Ending balance, shares at Mar. 31, 2015
 
105,883,157 
 
 
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parenthetical)
Mar. 31, 2015
Dec. 31, 2014
Statement of Stockholders' Equity [Abstract]
 
 
Common stock, par value
$ 0.0001 
$ 0.0001 
Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Operating activities
 
 
Net loss
$ (7,169)
$ (3,834)
Adjustments to reconcile net loss to net cash flows used in operating activities:
 
 
Depreciation and amortization
166 
191 
Stock-based compensation expense
98 
84 
Accretion of interest expense
158 
 
Warrant revaluation
 
(1,765)
Changes in operating assets and liabilities:
 
 
Accounts receivable
251 
(404)
Prepaid expenses and other current assets
41 
39 
Deferred inventory costs
102 
 
Inventories
(213)
242 
Deposits and other assets
48 
 
Due from related party
(125)
 
Accounts payable
449 
1,023 
Accrued expenses and other liabilities
59 
244 
Deferred revenue
(223)
71 
Net cash used in operating activities
(6,358)
(4,109)
Investing activities
 
 
Purchase of property and equipment
(103)
(21)
Net cash used in investing activities
(103)
(21)
Financing activities
 
 
Payments of financing costs from issuance of long-term debt and warrants
(50)
 
Net cash used in financing activities
(50)
 
Net decrease in cash and cash equivalents
(6,511)
(4,130)
Cash and cash equivalents at beginning of period
28,526 
9,845 
Cash and cash equivalents at end of period
22,015 
5,715 
Supplemental Disclosure of Cash Flow Information:
 
 
Transfer from inventories to property and equipment in the field
92 
161 
Deferred public offering costs in accounts payable and accrued expenses
41 
 
Interest paid
$ 225 
 
Nature of Operations
Nature of Operations

Note 1 Nature of Operations

The Company

Corindus Vascular Robotics, Inc. (the “Company”), a Nevada corporation (formerly named Your Internet Defender, Inc. (“YIDI”)), acquired Corindus, Inc., a privately-held company, in a reverse acquisition on August 12, 2014. The Company’s corporate headquarters and research and development facility are in Waltham, Massachusetts and the Company is engaged in the marketing, sales and development of robotic-assisted catheterization systems (“CorPath System”).

Since its inception on March 21, 2002, the Company has devoted its efforts principally to research and development, business development, and raising capital. In July 2012, the Company received clearance from the United States Food and Drug Administration to market its CorPath System in the United States and shipped its first commercial product under this clearance in September 2012. In 2013, the Company moved into the growth stage, investing in sales and marketing in order to build its customer base. The Company’s future capital requirements will depend upon many factors, including progress with developing, manufacturing and marketing its technologies, the time and costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietary rights, its ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including regulatory changes affecting medical procedure reimbursement, and overall economic conditions in the Company’s target markets.

Reverse Acquisition Transaction

On August 12, 2014, the Company, as the legal acquirer, consummated a reverse acquisition of Corindus, Inc., the accounting acquirer (the “Acquisition”) pursuant to the Securities Exchange and Acquisition Agreement (the “Acquisition Agreement”), entered into between the Company and Corindus, Inc. Prior to the Acquisition, all outstanding shares of Series A through E Redeemable Convertible Preferred Stock of Corindus, Inc. were converted into 2,811,499 shares of common stock of Corindus, Inc.

Pursuant to the terms of the Acquisition Agreement (i) all outstanding shares of common stock of Corindus, Inc., $0.01 par value per share, were exchanged for shares of Company common stock, $0.0001 par value per share, and (ii) all outstanding options and warrants to purchase shares of common stock of Corindus, Inc. were exchanged for or replaced with options and warrants to acquire shares of common stock of the Company. The exchange ratio was one for 25.00207 shares.

In accordance with ASC 805-40, Reverse Acquisitions, the historical capital stock account of Corindus, Inc. immediately prior to the Acquisition was carried forward and retroactively adjusted to reflect the par value of the outstanding stock of the Company, including the number of shares issued in the Acquisition as the Company is the surviving legal entity. Additionally, retained earnings of Corindus, Inc. has been carried forward after the Acquisition. All share and per share amounts in the consolidated financial statements and related notes have been retrospectively adjusted to reflect (i) the conversion of the Series A through E Redeemable Convertible Preferred Stock into common stock and (ii) the one for 25.00207 exchange of shares of common stock.

 

At the closing of the Acquisition, the Company transferred the former business of YIDI to a former officer, director and shareholder of YIDI, in exchange for the satisfaction of a promissory note issued to the former officer, director and shareholder in the principal amount of approximately $249 and the assumption of liabilities related to the former operations.

Immediately after the transfer of the former business of YIDI, the business of Corindus, Inc. became the sole focus of the combined company and the combined company’s name was changed to Corindus Vascular Robotics, Inc.

Liquidity

The Company has incurred losses since inception and has funded its operations primarily through the issuance of capital stock and debt. As of March 31, 2015, the Company had an accumulated deficit of $92,046, and net borrowings outstanding of $9,268, of which $3,089 is contractually due over the next 12 months.

The Company has cash resources of $22,015 and working capital of $18,129. The Company believes that these cash resources will be sufficient to meet the Company’s cash requirements through at least the next twelve months, including funding its anticipated losses and scheduled debt maturities. Additionally, the Company is in compliance with its debt covenant requirements as of March 31, 2015 and expects to remain in compliance over the next 12 months. As the Company continues to incur losses, a transition to profitability is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until doing so, intends to fund future operations through additional debt or equity offerings. There can be no assurances, however, that additional funding will be available on terms acceptable to the Company, if at all.

Significant Accounting Policies
Significant Accounting Policies
Note 2 Significant Accounting Policies

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 (“2014 Form 10-K”). The Company’s accounting policies are described in the “Notes to Consolidated Financial Statements” in the 2014 Form 10-K and are updated, as necessary, in this Form 10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from the audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three months ended March 31, 2015, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

 

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Corindus, Inc. and Corindus Security Corporation. Corindus, Inc. is our operating subsidiary, while Corindus Security Corporation was created solely to hold and invest the proceeds from issuance of equity. All intercompany transactions and balances have been eliminated in consolidation. The functional currency of both wholly-owned subsidiaries is the U.S. dollar and, therefore, the Company has not recorded any currency translation adjustments.

Reclassification

Sales and marketing expenses of $1,940 for the three months ended March 31, 2014 have been reclassified to selling, general and administrative expenses to conform to 2015 presentation.

Segment Information

The Company operates in one business segment, which is the marketing, sales and development of robotic-assisted vascular interventions.

Use of Estimates

The process of preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements. Such management estimates include those relating to revenue recognition, inventory write-downs to reflect net realizable value, assumptions used in the valuation of stock-based awards, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.

Significant Customers

The Company had three customers which accounted for 78% of its revenues during the three months ended March 31, 2014. The Company had three customers that accounted for 73% of its revenues during the three months ended March 31, 2015. The Company had two customers that accounted for 52% of the accounts receivable balance at December 31, 2014. The Company had two different customers that comprised 38% of the accounts receivable balance at March 31, 2015, exclusive of amounts due from related party, which are disclosed in Note 9.

Financial Instruments

Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy is used to prioritize the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements), and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:

 

    Level 1Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

 

    Level 2—Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.

 

    Level 3—Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

There were no assets and liabilities as of December 31, 2014 and March 31, 2015 that are measured and recorded in the financial statements at fair value on a recurring basis. There were no transfers between Level 1, 2 or 3 assets or liabilities during the three months ended March 31, 2014 and 2015.

Cash Equivalents

The Company considers highly liquid short-term investments, which typically have consisted of money market funds, with original maturity dates of three months or less at the date of purchase to be cash equivalents. From time to time, the Company’s cash balances may exceed federal deposit insurance limits. There were no amounts invested in money market funds at March 31, 2015 and December 31, 2014.

Inventories

Inventories are valued at the lower of cost or market using the first-in, first-out (“FIFO”) method. The Company routinely monitors the recoverability of its inventory and records the lower of cost or market reserves based on current selling prices and reserves for excess and obsolete inventory based on historical and forecasted usage, as required. Scrap and excess manufacturing costs are charged to cost of revenue as incurred and not capitalized as part of inventories.

Revenue Recognition

The CorPath System is a capital medical device used by hospitals and surgical centers to perform heart catheterizations. Use of the CorPath System requires a sterile, single-use cassette (the “CorPath Cassette”), which are sold separately, for each procedure. Products are sold to customers with no rights of return. The Company recognizes revenue on the sale of products when the following criteria are met:

 

    Persuasive evidence of an arrangement exists

 

    The price to the buyer is fixed or determinable

 

    Collectability is reasonably assured

 

    Risk of loss transfers and the product is delivered

 

In each arrangement, the Company is responsible for installation of the CorPath System and initial user training, which services are deemed essential to the functionality of the system. Therefore, the Company recognizes system revenue when the CorPath System is delivered, installed, and accepted by the end user customer.

Each CorPath System is sold with a standard one year warranty, which provides that the CorPath System will function as intended and during that one year period, the Company will either replace the product or a portion thereof or provide the necessary repair service during the Company’s normal service hours. The Company accrues for the estimated costs of the warranty once the CorPath System revenue is recognized.

The Company generally enters into multiple element arrangements, which include the sale of a CorPath System with an initial order of CorPath Cassettes, and may include either a basic service plan or a premium service plan. The basic service plan provides for an extended warranty period and the premium service plan provides for the extended warranty as well as component upgrades. Deliverables, which are accounted for as separate units of accounting under multiple-element arrangements include: (a) the CorPath System, including delivery installation and initial training, which are subject to customer acceptance and (b) the initial shipment of CorPath Cassettes to the customer, and may include either (c) a basic service plan or (d) a premium service plan.

The Company recognizes revenue on multiple-element arrangements in accordance with Accounting Standards Update (“ASU”) 2009-13, Revenue Recognition (Topic 605): Multiple Deliverable Revenue Arrangements, based on the estimated selling price of each element. In accordance with ASU 2009-13, the Company uses vendor-specific objective evidence (“VSOE”), if available, to determine the selling price of each element. If VSOE is not available, the Company uses third-party evidence (“TPE”) to determine the selling price. If TPE is not available, the Company uses its best estimate to develop the estimated selling price (“BESP”).

The Company uses BESP to determine the selling price of its systems as well as the basic and premium service plans. BESP is determined based on estimated costs plus a reasonable margin, and has generally been consistent with the price charged to the customer for such products and services. The determination of BESP also considers the price of the service plans charged to customers when such services are sold separately in subsequent transactions. The Company also uses BESP to determine the selling price of the initial order of cassettes, which considers the price at which it charges its customers when the cassettes are sold separately.

Revenue related to basic service plans is recognized on a straight-line basis over the life of the service contract. Revenue related to premium service plans is recognized over the life of the service contract, with consideration given to the expected timing of costs to be incurred related to the delivery of component upgrades. Revenues from accessories are recorded upon delivery and services provided by the Company outside of a basic or premium service contract are recognized as the services are provided.

There are no performance, cancellation, termination, or refund-type provisions under the Company’s multiple element arrangements.

 

On January 21, 2011, the Company entered into a distributor agreement with Philips Medical Systems Nederland, B.V. (“Philips”) appointing Philips to be the sole worldwide distributor for the promotion and sale of the Company’s CorPath System. Under the agreement, Philips sold the equipment directly to the end user and the Company was responsible for installation and initial training. Revenue was recognized on a net basis based on the amount billed to Philips and upon acceptance of the system by the end-user customer. This agreement with Philips expired on August 7, 2014.

The Company also sells CorPath Cassettes under a CorPath Utilization Program (“CUP”), which is a multi-year arrangement that involves the placement of a CorPath System at a customer’s site free of charge and the customer agrees to purchase a minimum number of CorPath Cassettes each month at a premium over the regular price. The Company records revenue upon shipment of the cassettes based on the selling price of the CorPath Cassettes. The system is capitalized as field equipment in property and equipment and is depreciated on a straight line basis through cost of revenue over the estimated useful life of the system, which generally approximates the length of the CUP program contract, which is typically 36 months. Revenues under this program have not been significant to date.

The Company also uses a One-Stent program to demonstrate its confidence in the CorPath System’s ability to help accurately measure anatomy and precisely place only one stent per lesion. The Company provides eligible customers registered under the program a $1 credit against future CorPath Cassette purchases for a qualifying CorPath percutaneous coronary intervention (“PCI”) procedure which uses more than one stent per lesion. The estimated cost of honoring the potential obligation under the stent program is recorded as a reduction of revenue at the time of shipment. These costs have not been significant to date.

The Company records shipping and handling costs as a selling expense in the period incurred, and records payments from customers for shipping costs as a reduction of selling expenses. Such amounts have not been material in the periods presented. The Company recorded medical device excise tax in the amount of $16 and $7 for the three months ended March 31, 2014 and 2015, respectively, which is included in selling, general and administrative expenses.

Warrants

The Company had warrants outstanding to purchase shares of Series A, D and E Redeemable Convertible Preferred Stock, which converted into warrants to purchase shares of common stock immediately prior to the Acquisition. The warrant instruments required mark to market accounting which were recorded in the statements of operations based on their fair values determined using the Black-Scholes model and the fair value of underlying preferred stock.

In connection with the Acquisition, the Company exchanged warrants to purchase 201,178 shares of Corindus, Inc. Series A, D and E Redeemable Convertible Preferred Stock at an average exercise price of $26.63 per share to warrants to purchase 5,029,865 shares of the Company’s common stock at the average exercise price of $1.07. The value of the warrants to purchase shares of Redeemable Convertible Preferred Stock were re-measured at each balance sheet date and any changes in the valuation were expensed in the period through the date of the Acquisition Agreement, at which point they were re-measured for the final time and reclassified to stockholders’ equity.

 

The Company estimated the fair value of these warrants using the Black-Scholes option pricing model based on the estimated market value of the underlying Redeemable Convertible Preferred Stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying redeemable convertible preferred stock. The Company revalued the warrants to purchase Series A and D Redeemable Convertible Preferred Stock on March 31, 2014 using the following assumptions: risk free interest of 1.14%, dividend yield of zero, expected volatility of 80% and expected years of 3.58.

Stock-Based Compensation

The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock award. The Company recognizes compensation costs resulting from the issuance of stock-based awards to non-employees as an expense in the consolidated statements of operations over the service period based on a measurement of fair value for each stock award at each performance date and period end.

Income Taxes

The Company accounts for income taxes using the liability method, whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable. Consistent with all prior periods, the Company did not record any income tax benefit for its operating losses for the three months ended March 31, 2014 and 2015 due to uncertainty regarding future taxable income.

Deferred Public Offering Costs

The Company has recorded approximately $41 of deferred offering costs associated with the proposed public offering of shares in 2015. The Company’s accounting policy is to record these direct costs as long-term assets included in deposits and other assets on the accompanying consolidated balance sheet at March 31, 2015, and reclassify the costs as a reduction to additional paid-in capital upon the completion of the proposed public offering or write-off the costs if and when the proposed public offering is not completed.

 

In January 2015, the FASB issued Financial Accounting Standards Update—Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. Subtopic 225-20, Income Statement—Extraordinary and Unusual Items, previously required that an entity separately classify, present, and disclose extraordinary events and transactions. This update is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 and may be applied prospectively or retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company is currently assessing the impact of this standard to its consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810) to address financial reporting considerations for the evaluation as to the requirement to consolidate certain legal entities. ASU 2015-02 is effective for fiscal years and for interim periods within those fiscal years beginning after December 15, 2015. The Company is evaluating the impact of ASU 2015-02 and if early adoption is appropriate in future reporting periods.

In April 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30) as part of the initiative to reduce complexity in accounting standards. The update requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for annual periods beginning after December 15, 2015 and for interim periods within those fiscal years. The Company is evaluating the impact of ASU 2015-03, and if early adoption is appropriate in future reporting periods.

Inventories
Inventories
Note 3 Inventories

Inventories are valued at the lower of cost or market using the FIFO method and consist of the following:

 

     December 31,
2014
     March 31,
2015
 

Raw material

   $ 861       $ 904   

Work in progress

     198         92   

Finished goods

     460         644   
  

 

 

    

 

 

 
$ 1,519    $ 1,640   
  

 

 

    

 

 

Reverse Acquisition
Reverse Acquisition

Note 4 Reverse Acquisition

As discussed in Note 1, in August 2014, Corindus, Inc., as the accounting acquirer, acquired the operations of the YIDI business and then immediately transferred YIDI’s operations to a former officer, director and shareholder of YIDI in exchange for the satisfaction of a promissory note issued to YIDI’s former officer, director and shareholder in the principal amount of approximately $249 and the assumption of liabilities related to the former operations.

Prior to the divestiture of YIDI’s former business, the Company performed an allocation of the purchase price for YIDI based on estimated fair value of the acquired assets and liabilities prior to the disposition of the remaining business of YIDI:

 

Purchase price assumption of note payable to former officer

$ 249   
  

 

 

 

Allocation of purchase price:

Intangible assets acquired

$ 262   

Accrued expense assumed

  (13
  

 

 

 

Net assets acquired

$ 249   
  

 

 

 

The results of operations for YIDI were immaterial for the three months ended March 31, 2014, and as such, no pro forma statement of operations data is presented.

The purchase accounting related to the acquisition was completed during the first quarter of 2015 and there were no adjustments made.

Long-Term Debt
Long-Term Debt

Note 5 Long-Term Debt

On June 11, 2014, the Company entered into a Loan and Security Agreement pursuant to which the lender agreed to make available to the Company $10,000 in two separate $5,000 loans under secured promissory notes. The initial note was made on June 11, 2014 in an aggregate principal amount equal to $5,000 (the “Initial Promissory Note”) and is repayable in equal monthly installments of principal and interest over 27 months beginning on July 1, 2015. Prior to July 1, 2015, the Company is required to make interest only payments. The Initial Promissory Note bears interest at a rate equal to the greater of (a) 11.25% or (b) 11.25% plus the Wall Street Journal Prime Rate, less 3.25%, and includes an additional interest payment of $125 due no later than October 1, 2017, which is accreted over the term of the loan.

On December 31, 2014, the Company borrowed the additional $5,000 (the “Second Promissory Note”) under the Loan and Security Agreement. The Second Promissory note is also repayable in equal monthly installments of principal and interest over 27 months beginning on July 1, 2015. Prior to July 1, 2015, the Company is required to make interest only payments. The Second Promissory Note bears interest at a rate equal to the greater of (a) 9.95% or (b) 9.95% plus the Wall Street Journal Prime Rate, less 3.25%, and also includes an additional interest payment of $125 due no later than October 1, 2017, which is accreted over the term of the loan. The notes are secured by substantially all the assets of the Company.

In connection with the Initial Promissory Note, the Company issued the lender warrants to purchase 177,514 shares of the Company’s common stock at an exercise price of $1.41 per share. The fair value of the warrant issued to the lender was determined to be $230 at the date of issuance, and was recorded as a discount on the debt. Additionally, in connection with the Second Promissory Note, the Company issued the lender warrants to purchase 177,514 shares of the Company’s common stock at an exercise price of $1.41 per share. The fair value of the warrant issued to the lender was determined to be $619 at the date of issuance, and was recorded as a discount on the debt. The Company amortizes the debt discount to interest expense over the term of the debt using the effective interest method.

The Loan and Security Agreement also contains covenants which include certain restrictions with respect to subsequent indebtedness, liens, loans and investments, asset sales and share repurchases and other restricted payments, subject to certain exceptions. The Loan and Security Agreement also contains financial reporting obligations. An event of default under the Loan and Security Agreement includes, but is not limited to, breach of covenants, insolvency, and occurrence of any default under any agreement or obligation of the Company.

Stock-based Compensation
Stock-based Compensation
Note 6 Stock-based Compensation

Stock-based compensation expense was allocated based on the employees’ or non-employees’ function as follows:

 

     Three Months Ended March 31,  
     2014      2015  

Research and development

   $ 15       $ 17   

Selling, general and administrative

     69         81   
  

 

 

    

 

 

 
$ 84    $ 98   
  

 

 

    

 

 

 

The Company granted options to purchase 550,044 shares of common stock at an exercise price of $0.75 per share during the three months ended March 31, 2014. The Company granted options to purchase 117,500 shares of common stock at an exercise price of $4.25 per share during the three months ended March 31, 2015. The weighted-average fair value of the stock options granted was $0.06 per share and $2.94 per share for the three months ended March 31, 2014 and 2015, respectively.

The following assumptions were used to estimate the fair value of stock options granted using the Black-Scholes Merton option-pricing model (“Black Scholes Model”):

 

     Three Months Ended March 31,  
     2014     2015  

Risk-free interest rate

     2.01     1.28

Expected term in years

     6.25        6.25   

Expected volatility

     80     80

Expected dividend yield

     0     0
Net Loss per Share
Net Loss per Share
Note 7 Net Loss per Share

Net loss per share for all periods presented is based on the equity structure of the legal acquirer, which assumes common stock is outstanding and is reflected on a retrospective basis for all periods presented of the conversion of Corindus, Inc.’s preferred stock and common stock into shares of the Company’s common stock. Basic net loss per share is computed by dividing net loss by the weighted average shares of common stock outstanding for each period. Diluted net loss per share is the same as basic net loss per share since the Company has net losses for each period presented. The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:

 

     Three Months Ended
March 31,
 
     2014      2015  

Options to purchase common stock

     9,063,275         8,779,622   

Warrants to purchase common stock

     4,852,351         5,207,379   
  

 

 

    

 

 

 

Total

  13,915,626      13,987,001   
  

 

 

    

 

 

 
Restructuring Charge
Restructuring Charge
Note 8 Restructuring Charge

During the three months ended March 31, 2014, the Company initiated reductions in workforce to control costs while the Company pursued new financing alternatives. For the three months ended March 31, 2014, the Company recorded $93 in restructuring charges for severance and related costs, which were paid in 2014.

Related Party Transactions
Related Party Transactions
Note 9 Related Party Transactions

Philips Medical Systems Nederland B.V.

On January 21, 2011, Corindus, Inc. entered into a distributor agreement with Philips, a shareholder of the Company and represented on the Company’s board of directors, appointing Philips to be a distributor for the promotion and sale of the Company’s CorPath System. This agreement provided that it would remain in force for two years from (a) the later of FDA approval of the CorPath System or (b) the date of notification by the Company to Philips of minimum inventory levels available for shipment. As required by the agreement, the Company notified Philips on August 7, 2012 of the commencement of the two-year term and the distribution agreement expired on August 7, 2014. The Company continues to sell CorPath Systems through Philips on a sale by sale basis under a non-exclusive arrangement under mutually agreeable terms, which may include a continued level of discounted pricing, until such time the Company either executes a new distribution arrangement with Philips or the Company no longer does business with Philips.

For the three months ended March 31, 2014 and 2015, the Company recorded revenues of $190 and $125 respectively, from shipments to Philips. At December 31, 2014 and March 31, 2015, Philips owed the Company $0 and $125, respectively, resulting from selling activity under the agreement.

 

Shareholder Loans

On June 14, 2010, the Company loaned funds to certain stockholders of the Company for tax payments to be made to the Israel Tax Authority in connection with a tax ruling related to a reorganization that took place in 2008 and the Company received non-interest bearing notes receivable, which documented such loans. Total amount of notes receivable issued was $145.

The notes receivable are repayable upon the disposition of the Company’s common stock by the existing shareholder. Notes receivable amounted to $136 at December 31, 2014 and March 31, 2015. The Company assessed the notes receivable for impairment and concluded that there were no impairment indicators at December 31, 2014 and March 31, 2015. The Company does not believe there is any significant collection risk associated with the notes receivable at March 31, 2015.

Not for Profit

In the fourth quarter of 2014, the Company participated in the formation of a not-for-profit, which was established to generate awareness of the health risks linked to the use of fluoroscopy in hospital catheterization procedures. The Company’s Chief Executive Officer and one of its senior executives represent two of the three voting members of the board of directors of the entity. As a result, under the voting model used for the consolidation of related parties and because the Company controls the entity by its representation on the board of directors of the entity, the Company has consolidated the financial statements of the entity. The not-for-profit has an immaterial amount of assets and liabilities on its balance sheet at December 31, 2014 and March 31, 2015 and expenses of $104 for the three months ended March 31, 2015.

Subsequent Events
Subsequent Events
Note 10 Subsequent Events

On April 30, 2015, our Board of Directors and shareholders owning a majority of the Company’s outstanding shares of common stock approved an increase in the authorized shares of common stock under the 2014 Stock Award Plan from 9,035,016 shares to 18,661,856 shares.

Significant Accounting Policies (Policies)

Basis of Presentation

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 (“2014 Form 10-K”). The Company’s accounting policies are described in the “Notes to Consolidated Financial Statements” in the 2014 Form 10-K and are updated, as necessary, in this Form 10-Q. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from the audited financial statements, but does not include all disclosures required by U.S. GAAP. The results of operations for the three months ended March 31, 2015, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Corindus, Inc. and Corindus Security Corporation. Corindus, Inc. is our operating subsidiary, while Corindus Security Corporation was created solely to hold and invest the proceeds from issuance of equity. All intercompany transactions and balances have been eliminated in consolidation. The functional currency of both wholly-owned subsidiaries is the U.S. dollar and, therefore, the Company has not recorded any currency translation adjustments.

Reclassification

Sales and marketing expenses of $1,940 for the three months ended March 31, 2014 have been reclassified to selling, general and administrative expenses to conform to 2015 presentation.

Segment Information

The Company operates in one business segment, which is the marketing, sales and development of robotic-assisted vascular interventions

Use of Estimates

The process of preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements. Such management estimates include those relating to revenue recognition, inventory write-downs to reflect net realizable value, assumptions used in the valuation of stock-based awards, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.

Significant Customers

The Company had three customers which accounted for 78% of its revenues during the three months ended March 31, 2014. The Company had three customers that accounted for 73% of its revenues during the three months ended March 31, 2015. The Company had two customers that accounted for 52% of the accounts receivable balance at December 31, 2014. The Company had two different customers that comprised 38% of the accounts receivable balance at March 31, 2015, exclusive of amounts due from related party, which are disclosed in Note 9.

Financial Instruments

Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy is used to prioritize the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements), and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:

 

    Level 1Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

 

    Level 2—Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.

 

    Level 3—Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.

There were no assets and liabilities as of December 31, 2014 and March 31, 2015 that are measured and recorded in the financial statements at fair value on a recurring basis. There were no transfers between Level 1, 2 or 3 assets or liabilities during the three months ended March 31, 2014 and 2015.

Cash Equivalents

The Company considers highly liquid short-term investments, which typically have consisted of money market funds, with original maturity dates of three months or less at the date of purchase to be cash equivalents. From time to time, the Company’s cash balances may exceed federal deposit insurance limits. There were no amounts invested in money market funds at March 31, 2015 and December 31, 2014.

Inventories

Inventories are valued at the lower of cost or market using the first-in, first-out (“FIFO”) method. The Company routinely monitors the recoverability of its inventory and records the lower of cost or market reserves based on current selling prices and reserves for excess and obsolete inventory based on historical and forecasted usage, as required. Scrap and excess manufacturing costs are charged to cost of revenue as incurred and not capitalized as part of inventories.

Revenue Recognition

The CorPath System is a capital medical device used by hospitals and surgical centers to perform heart catheterizations. Use of the CorPath System requires a sterile, single-use cassette (the “CorPath Cassette”), which are sold separately, for each procedure. Products are sold to customers with no rights of return. The Company recognizes revenue on the sale of products when the following criteria are met:

 

    Persuasive evidence of an arrangement exists

 

    The price to the buyer is fixed or determinable

 

    Collectability is reasonably assured

 

    Risk of loss transfers and the product is delivered

 

In each arrangement, the Company is responsible for installation of the CorPath System and initial user training, which services are deemed essential to the functionality of the system. Therefore, the Company recognizes system revenue when the CorPath System is delivered, installed, and accepted by the end user customer.

Each CorPath System is sold with a standard one year warranty, which provides that the CorPath System will function as intended and during that one year period, the Company will either replace the product or a portion thereof or provide the necessary repair service during the Company’s normal service hours. The Company accrues for the estimated costs of the warranty once the CorPath System revenue is recognized.

The Company generally enters into multiple element arrangements, which include the sale of a CorPath System with an initial order of CorPath Cassettes, and may include either a basic service plan or a premium service plan. The basic service plan provides for an extended warranty period and the premium service plan provides for the extended warranty as well as component upgrades. Deliverables, which are accounted for as separate units of accounting under multiple-element arrangements include: (a) the CorPath System, including delivery installation and initial training, which are subject to customer acceptance and (b) the initial shipment of CorPath Cassettes to the customer, and may include either (c) a basic service plan or (d) a premium service plan.

The Company recognizes revenue on multiple-element arrangements in accordance with Accounting Standards Update (“ASU”) 2009-13, Revenue Recognition (Topic 605): Multiple Deliverable Revenue Arrangements, based on the estimated selling price of each element. In accordance with ASU 2009-13, the Company uses vendor-specific objective evidence (“VSOE”), if available, to determine the selling price of each element. If VSOE is not available, the Company uses third-party evidence (“TPE”) to determine the selling price. If TPE is not available, the Company uses its best estimate to develop the estimated selling price (“BESP”).

The Company uses BESP to determine the selling price of its systems as well as the basic and premium service plans. BESP is determined based on estimated costs plus a reasonable margin, and has generally been consistent with the price charged to the customer for such products and services. The determination of BESP also considers the price of the service plans charged to customers when such services are sold separately in subsequent transactions. The Company also uses BESP to determine the selling price of the initial order of cassettes, which considers the price at which it charges its customers when the cassettes are sold separately.

Revenue related to basic service plans is recognized on a straight-line basis over the life of the service contract. Revenue related to premium service plans is recognized over the life of the service contract, with consideration given to the expected timing of costs to be incurred related to the delivery of component upgrades. Revenues from accessories are recorded upon delivery and services provided by the Company outside of a basic or premium service contract are recognized as the services are provided.

There are no performance, cancellation, termination, or refund-type provisions under the Company’s multiple element arrangements.

 

On January 21, 2011, the Company entered into a distributor agreement with Philips Medical Systems Nederland, B.V. (“Philips”) appointing Philips to be the sole worldwide distributor for the promotion and sale of the Company’s CorPath System. Under the agreement, Philips sold the equipment directly to the end user and the Company was responsible for installation and initial training. Revenue was recognized on a net basis based on the amount billed to Philips and upon acceptance of the system by the end-user customer. This agreement with Philips expired on August 7, 2014.

The Company also sells CorPath Cassettes under a CorPath Utilization Program (“CUP”), which is a multi-year arrangement that involves the placement of a CorPath System at a customer’s site free of charge and the customer agrees to purchase a minimum number of CorPath Cassettes each month at a premium over the regular price. The Company records revenue upon shipment of the cassettes based on the selling price of the CorPath Cassettes. The system is capitalized as field equipment in property and equipment and is depreciated on a straight line basis through cost of revenue over the estimated useful life of the system, which generally approximates the length of the CUP program contract, which is typically 36 months. Revenues under this program have not been significant to date.

The Company also uses a One-Stent program to demonstrate its confidence in the CorPath System’s ability to help accurately measure anatomy and precisely place only one stent per lesion. The Company provides eligible customers registered under the program a $1 credit against future CorPath Cassette purchases for a qualifying CorPath percutaneous coronary intervention (“PCI”) procedure which uses more than one stent per lesion. The estimated cost of honoring the potential obligation under the stent program is recorded as a reduction of revenue at the time of shipment. These costs have not been significant to date.

The Company records shipping and handling costs as a selling expense in the period incurred, and records payments from customers for shipping costs as a reduction of selling expenses. Such amounts have not been material in the periods presented. The Company recorded medical device excise tax in the amount of $16 and $7 for the three months ended March 31, 2014 and 2015, respectively, which is included in selling, general and administrative expenses.

Warrants

The Company had warrants outstanding to purchase shares of Series A, D and E Redeemable Convertible Preferred Stock, which converted into warrants to purchase shares of common stock immediately prior to the Acquisition. The warrant instruments required mark to market accounting which were recorded in the statements of operations based on their fair values determined using the Black-Scholes model and the fair value of underlying preferred stock.

In connection with the Acquisition, the Company exchanged warrants to purchase 201,178 shares of Corindus, Inc. Series A, D and E Redeemable Convertible Preferred Stock at an average exercise price of $26.63 per share to warrants to purchase 5,029,865 shares of the Company’s common stock at the average exercise price of $1.07. The value of the warrants to purchase shares of Redeemable Convertible Preferred Stock were re-measured at each balance sheet date and any changes in the valuation were expensed in the period through the date of the Acquisition Agreement, at which point they were re-measured for the final time and reclassified to stockholders’ equity.

 

The Company estimated the fair value of these warrants using the Black-Scholes option pricing model based on the estimated market value of the underlying Redeemable Convertible Preferred Stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying redeemable convertible preferred stock. The Company revalued the warrants to purchase Series A and D Redeemable Convertible Preferred Stock on March 31, 2014 using the following assumptions: risk free interest of 1.14%, dividend yield of zero, expected volatility of 80% and expected years of 3.58.

Stock-Based Compensation

The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock award. The Company recognizes compensation costs resulting from the issuance of stock-based awards to non-employees as an expense in the consolidated statements of operations over the service period based on a measurement of fair value for each stock award at each performance date and period end.

Income Taxes

The Company accounts for income taxes using the liability method, whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable. Consistent with all prior periods, the Company did not record any income tax benefit for its operating losses for the three months ended March 31, 2014 and 2015 due to uncertainty regarding future taxable income.

Deferred Public Offering Costs

The Company has recorded approximately $41 of deferred offering costs associated with the proposed public offering of shares in 2015. The Company’s accounting policy is to record these direct costs as long-term assets included in deposits and other assets on the accompanying consolidated balance sheet at March 31, 2015, and reclassify the costs as a reduction to additional paid-in capital upon the completion of the proposed public offering or write-off the costs if and when the proposed public offering is not completed.

In January 2015, the FASB issued Financial Accounting Standards Update—Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. Subtopic 225-20, Income Statement—Extraordinary and Unusual Items, previously required that an entity separately classify, present, and disclose extraordinary events and transactions. This update is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 and may be applied prospectively or retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company is currently assessing the impact of this standard to its consolidated financial statements.

In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810) to address financial reporting considerations for the evaluation as to the requirement to consolidate certain legal entities. ASU 2015-02 is effective for fiscal years and for interim periods within those fiscal years beginning after December 15, 2015. The Company is evaluating the impact of ASU 2015-02 and if early adoption is appropriate in future reporting periods.

In April 2015, the FASB issued ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30) as part of the initiative to reduce complexity in accounting standards. The update requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for annual periods beginning after December 15, 2015 and for interim periods within those fiscal years. The Company is evaluating the impact of ASU 2015-03, and if early adoption is appropriate in future reporting periods.

Inventories (Tables)
Schedule of Inventories Valued under FIFO Method

Inventories are valued at the lower of cost or market using the FIFO method and consist of the following:

 

     December 31,
2014
     March 31,
2015
 

Raw material

   $ 861       $ 904   

Work in progress

     198         92   

Finished goods

     460         644   
  

 

 

    

 

 

 
$ 1,519    $ 1,640   
  

 

 

    

 

 

Reverse Acquisition (Tables)
Schedule of Business Acquisitions

Prior to the divestiture of YIDI’s former business, the Company performed an allocation of the purchase price for YIDI based on estimated fair value of the acquired assets and liabilities prior to the disposition of the remaining business of YIDI:

 

Purchase price assumption of note payable to former officer

$ 249   
  

 

 

 

Allocation of purchase price:

Intangible assets acquired

$ 262   

Accrued expense assumed

  (13
  

 

 

 

Net assets acquired

$ 249   
  

 

 

 
Stock-based Compensation (Tables)

Stock-based compensation expense was allocated based on the employees’ or non-employees’ function as follows:

 

     Three Months Ended March 31,  
     2014      2015  

Research and development

   $ 15       $ 17   

Selling, general and administrative

     69         81   
  

 

 

    

 

 

 
$ 84    $ 98   
  

 

 

    

 

 

 

The following assumptions were used to estimate the fair value of stock options granted using the Black-Scholes Merton option-pricing model (“Black Scholes Model”):

 

     Three Months Ended March 31,  
     2014     2015  

Risk-free interest rate

     2.01     1.28

Expected term in years

     6.25        6.25   

Expected volatility

     80     80

Expected dividend yield

     0     0

 

Net Loss per Share (Tables)
Schedule of Securities Excluded from Computation of Net Loss per Share

The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:

 

     Three Months Ended
March 31,
 
     2014      2015  

Options to purchase common stock

     9,063,275         8,779,622   

Warrants to purchase common stock

     4,852,351         5,207,379   
  

 

 

    

 

 

 

Total

  13,915,626      13,987,001   
  

 

 

    

 

 

 
Nature of Operations - Additional Information (Detail) (USD $)
In Thousands, except Per Share data, unless otherwise specified
0 Months Ended 3 Months Ended
Aug. 12, 2014
Mar. 31, 2015
Dec. 31, 2014
Mar. 31, 2014
Dec. 31, 2013
Description of acquisition agreement
 
(i) all outstanding shares of common stock of Corindus, Inc., $0.01 par value per share, were exchanged for shares of Company common stock, $0.0001 par value per share, and (ii) all outstanding options and warrants to purchase shares of common stock of Corindus, Inc. were exchanged for or replaced with options and warrants to acquire shares of common stock of the Company 
 
 
 
Common stock, par value
 
$ 0.0001 
$ 0.0001 
 
 
Description of exchange ratio
 
The exchange ratio was one for 25.00207 shares 
 
 
 
Transfer of former business in satisfaction of promissory note
$ 249 
 
 
 
 
Accumulated deficit
 
92,046 
84,877 
 
 
Net borrowings outstanding
 
9,268 
 
 
 
Contractual obligation due over next 12 months
 
3,089 
 
 
 
Cash and cash equivalents
 
22,015 
28,526 
5,715 
9,845 
Working capital
 
$ 18,129 
 
 
 
Debt covenant maturity description
 
Over the next 12 months 
 
 
 
Reverse acquisition - YIDI [Member]
 
 
 
 
 
Exchange ratio of common stock
25.00207 
 
 
 
 
Significant Accounting Policies - Additional Information (Detail) (USD $)
3 Months Ended 3 Months Ended 12 Months Ended 0 Months Ended
Mar. 31, 2015
Segments
Mar. 31, 2014
Dec. 31, 2014
Mar. 31, 2015
Revenues [Member]
Customer Concentration Risk [Member]
Customer
Mar. 31, 2014
Revenues [Member]
Customer Concentration Risk [Member]
Customer
Mar. 31, 2015
Accounts Receivable [Member]
Customer Concentration Risk [Member]
Customer
Dec. 31, 2014
Accounts Receivable [Member]
Customer Concentration Risk [Member]
Customer
Mar. 31, 2015
Fair Value, Measurements, Recurring [Member]
Dec. 31, 2014
Fair Value, Measurements, Recurring [Member]
Mar. 31, 2015
Common Stock $0.0001 Par Value [Member]
Mar. 31, 2015
Redeemable Convertible Preferred Stock [Member]
Mar. 31, 2014
Series A- and D- Redeemable Convertible Preferred Stock [Member]
Warrant [Member]
Significant Accounting Policies [Line Items]
 
 
 
 
 
 
 
 
 
 
 
 
Sales and marketing expenses
 
$ 1,940,000 
 
 
 
 
 
 
 
 
 
 
Number of segments
 
 
 
 
 
 
 
 
 
 
 
Concentration percentage
 
 
 
73.00% 
78.00% 
38.00% 
52.00% 
 
 
 
 
 
Number of customers
 
 
 
 
 
 
 
 
Assets fair value on recurring basis
 
 
 
 
 
 
 
 
 
 
Liabilities fair value on recurring basis
 
 
 
 
 
 
 
 
 
 
Transfer of between level 1 and level 2 assets
 
 
 
 
 
 
 
 
 
 
Transfer of between level 1 and level 2 liabilities
 
 
 
 
 
 
 
 
 
 
Amount invested in money market funds
 
 
 
 
 
 
 
 
 
 
Warranty period of systems sold
1 year 
 
 
 
 
 
 
 
 
 
 
 
Estimated useful lives
36 months 
 
 
 
 
 
 
 
 
 
 
 
Credit provided to eligible customers
1,000 
 
 
 
 
 
 
 
 
 
 
 
Medical device excise tax
7,000 
16,000 
 
 
 
 
 
 
 
 
 
 
Number of shares callable by warrants outstanding
 
 
 
 
 
 
 
 
 
5,029,865 
201,178 
 
Average exercise price of warrant
 
 
 
 
 
 
 
 
 
$ 1.07 
$ 26.63 
 
Fair value assumptions, risk free interest rate
 
 
 
 
 
 
 
 
 
 
 
1.14% 
Fair value assumptions, dividend yield
 
 
 
 
 
 
 
 
 
 
 
80.00% 
Fair value assumptions, expected volatility rate
 
 
 
 
 
 
 
 
 
 
 
0.00% 
Fair value assumptions, expected term
 
 
 
 
 
 
 
 
 
 
 
3 years 6 months 29 days 
Income tax benefit
 
 
 
 
 
 
 
 
 
 
Deferred offering costs
$ 41,000 
 
 
 
 
 
 
 
 
 
 
 
Inventories - Schedule of Inventories Valued under FIFO Method (Detail) (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2015
Dec. 31, 2014
Inventory Disclosure [Abstract]
 
 
Raw materials
$ 904 
$ 861 
Work in progress
92 
198 
Finished goods
644 
460 
Inventories, net
$ 1,640 
$ 1,519 
Reverse Acquisition - Additional Information (Detail) (Reverse acquisition - YIDI [Member], USD $)
In Thousands, unless otherwise specified
Aug. 31, 2014
Reverse acquisition - YIDI [Member]
 
Business Acquisition [Line Items]
 
Promissory note
$ 249 
Reverse Acquisition - Schedule of Business Acquisitions (Detail) (Reverse acquisition - YIDI [Member], USD $)
In Thousands, unless otherwise specified
1 Months Ended
Aug. 31, 2014
Reverse acquisition - YIDI [Member]
 
Business Acquisition [Line Items]
 
Purchase price-assumption of note payable to former officer
$ 249 
Allocation of purchase price:
 
Intangible assets acquired
262 
Accrued expense assumed
(13)
Net assets acquired
$ 249 
Long-Term Debt - Additional Information (Detail) (Loan and Security Agreement [Member], USD $)
In Thousands, except Share data, unless otherwise specified
0 Months Ended 3 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2015
Jun. 11, 2014
Jun. 11, 2014
Initial Promissory Note [Member]
Mar. 31, 2015
Initial Promissory Note [Member]
Jul. 11, 2014
Initial Promissory Note [Member]
Jun. 11, 2014
Initial Promissory Note [Member]
Mar. 31, 2015
Second Promissory Note [Member]
Dec. 31, 2014
Second Promissory Note [Member]
Line of Credit Facility [Line Items]
 
 
 
 
 
 
 
 
Available borrowing under Loan and Security Agreement
 
$ 10,000 
 
 
 
 
 
 
Amount of each separate note
5,000 
 
 
 
 
5,000 
 
5,000 
Note issuance date
 
 
Jun. 11, 2014 
 
 
 
 
 
Frequency of debt payments
 
 
 
Monthly 
 
 
Monthly 
 
Term of debt payments
 
 
27 months 
 
 
 
 
27 months 
Date of first required payment
 
 
Jul. 01, 2015 
 
 
 
 
Jul. 01, 2015 
Interest rate, minimum
 
 
11.25% 
 
 
 
 
9.95% 
Interest rate, description of maximum
 
 
 
11.25% plus the Wall Street Journal Prime Rate, less 3.25% 
 
 
9.95% plus the Wall Street Journal Prime Rate, less 3.25% 
 
Spread on variable rate
 
 
3.25% 
 
 
 
 
 
Additional interest payment
 
 
125 
 
 
 
 
125 
Due date of additional interest payment
 
 
Oct. 01, 2017 
 
 
 
 
Oct. 01, 2017 
Number of shares callable by warrants outstanding
 
 
 
 
177,514 
 
177,514 
 
Exercise price of warrant
 
 
 
 
$ 1.41 
 
$ 1.41 
 
Fair value of the warrant issued
 
 
 
 
$ 230 
 
$ 619 
 
Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
 
 
Stock-based compensation expense
$ 98 
$ 84 
Research and Development [Member]
 
 
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
 
 
Stock-based compensation expense
17 
15 
Selling General and Administrative [Member]
 
 
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
 
 
Stock-based compensation expense
$ 81 
$ 69 
Stock-Based Compensation - Additional Information (Detail) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
 
 
Numbers of options grant
117,500 
550,044 
Option exercise price
$ 4.25 
$ 0.75 
Weighted average grant date fair value of options granted
$ 2.94 
$ 0.06 
Stock-based Compensation - Summary of Assumptions Used to Estimate the Fair Value of the Stock Options Granted (Detail)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
 
 
Risk-free interest rate
1.28% 
2.01% 
Expected term in years
6 years 3 months 
6 years 3 months 
Expected volatility
80.00% 
80.00% 
Expected dividend yield
0.00% 
0.00% 
Net Loss per Share - Schedule of Securities Excluded from Computation of Net Loss per Share (Detail)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
 
 
Number of anti-dilutive securities
13,987,001 
13,915,626 
Options to Purchase Common Stock [Member]
 
 
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
 
 
Number of anti-dilutive securities
8,779,622 
9,063,275 
Warrant [Member]
 
 
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
 
 
Number of anti-dilutive securities
5,207,379 
4,852,351 
Restructuring Charge - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
Mar. 31, 2014
Restructuring and Related Activities [Abstract]
 
Restructuring charges - severance and related costs
$ 93 
Related Party Transactions - Additional Information (Detail) (USD $)
0 Months Ended 3 Months Ended 0 Months Ended 3 Months Ended 12 Months Ended 3 Months Ended
Mar. 31, 2015
Dec. 31, 2014
Jan. 21, 2011
Philips Medical Systems [Member]
Mar. 31, 2015
Philips Medical Systems [Member]
Mar. 31, 2014
Philips Medical Systems [Member]
Dec. 31, 2014
Philips Medical Systems [Member]
Jun. 14, 2010
Shareholders [Member]
Mar. 31, 2015
Shareholders [Member]
Dec. 31, 2014
Shareholders [Member]
Mar. 31, 2015
Shareholders [Member]
Notes Receivable [Member]
Dec. 31, 2014
Shareholders [Member]
Notes Receivable [Member]
Mar. 31, 2015
Not For Profit [Member]
Related Party Transaction [Line Items]
 
 
 
 
 
 
 
 
 
 
 
 
Term of the consulting agreement
 
 
2 years 
 
 
 
 
 
 
 
 
 
Revenue from related party
 
 
 
$ 125,000 
$ 190,000 
 
 
 
 
 
 
 
Due from related party
125,000 
 
 
125,000 
 
 
 
 
 
 
 
Issuance of notes receivable due from stockholder
 
 
 
 
 
 
145,000 
 
 
 
 
 
Notes receivable due from stockholders
136,000 
136,000 
 
 
 
 
 
136,000 
136,000 
 
 
 
Impairment cost for notes receivable
 
 
 
 
 
 
 
 
 
 
Related party transaction expense
 
 
 
 
 
 
 
 
 
 
 
$ 104,000 
Subsequent Events - Additional Information (Detail) (The 2014 Stock Award Plan [Member])
Mar. 31, 2015
Apr. 30, 2015
Subsequent Event [Member]
Subsequent Event [Line Items]
 
 
Number of authorized shares of common stock under plan
9,035,016 
18,661,856